NASDAQ: CALCCalcimedica Inc Stock
$4.59+0.07 (+1.55%)
Updated Apr 23, 2024
CALC Price
$4.59
Fair Value Price
N/A
Market Cap
$49.30M
52 Week Low
$1.75
52 Week High
$8.59
P/E
-0.6x
P/B
6.04x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$34.36M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.49
Operating Cash Flow
-$26M
Beta
0.62
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
CALC Overview
Graybug Vision, Inc. is a clinical-stage biopharmaceutical company developing treatments of retina and optic nerve diseases. Known as Graybug LLC until 2016, Graybug Vision was incorporated in 2011 and is based in Redwood City, CA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CALC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CALC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CALC is poor value based on its book value relative to its share price (6.04x), compared to the US Biotechnology industry average (5.93x)
P/B vs Industry Valuation
CALC is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CALC due diligence checks available for Premium users.
Be the first to know about important CALC news, forecast changes, insider trades & much more!
CALC News
Valuation
CALC fair value
Fair Value of CALC stock based on Discounted Cash Flow (DCF)
Price
$4.59
Fair Value
$11.14
Undervalued by
58.80%
CALC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CALC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.6x
Industry
16.46x
Market
41.92x
CALC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.04x
Industry
5.93x
CALC is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CALC's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.1M
Profit Margin
0%
CALC's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$12.2M
Liabilities
$4.0M
Debt to equity
0.49
CALC's short-term assets ($11.61M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CALC's short-term assets ($11.61M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CALC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CALC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.6M
Investing
-$2.7M
Financing
$175.0k
CALC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CALC vs Biotech Stocks
Calcimedica Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.